基于碳醇的三环化合物的抗癌活性的审查
Hua Zhang1,2, Wen Zhang1,2, Mengyu Zhu1,2
1Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, China.
Current medicinal chemistry
|August 25, 2023
概括
新型碳醇衍生物在癌症治疗中表现有前途. 本综述探讨了卡博林和迪阿扎卡巴索尔化合物,强调了迪阿扎卡巴索尔作为开发抗癌剂的潜在新途径.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 癌症研究 癌症研究
背景情况:
- 癌症对全球健康造成重大负担,需要新的治疗策略.
- 现有的抗癌药物面临着包括副作用和耐药性在内的局限性,从而产生了对新化学型的需求.
研究的目的:
- 审查基于碳素的化合物,特别是碳素和碳素衍生物的抗癌潜力.
- 突出迪阿萨卡巴醇衍生物作为一个未经探索的领域,具有治疗前景.
- 介绍关键的碳素基三环结构的合成方法.
主要方法:
- 文献综述侧重于具有抗癌活性的碳醇衍生物.
- 分析合成路径,用于构建基于碳醇的支架.
- 评估报告的生物数据对卡博林和迪阿扎卡巴佐尔化合物.
主要成果:
- 碳醇衍生物,包括碳醇和碳醇,表现出显著的抗癌特性.
- 迪亚扎卡巴醇衍生物代表了一个较少探索的类别,具有开发新型抗癌药物的潜力.
- 概述了碳素三环系统的关键合成策略.
结论:
- 基于碳醇的化合物,特别是碳醇,为开发下一代抗癌疗法提供了有前途的途径.
- 为了克服癌症治疗当前面临的挑战,需要进一步探索二甲醇衍生物.
- 有效的合成方法对于获得这些潜在的有价值的抗癌剂至关重要.
相关概念视频
Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...


